Drugs / Sembragiline
Sembragiline
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01677754 | Oct 2012 → Jun 2015 | Alzheimer disease | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sembragiline | “BACKGROUND: Sembragiline is a potent, selective, long-acting, and reversible MAO-B inhibitor developed as a potential treatment for Alzheimer's disease (AD).” PMID 28550255 ↗ 2017 |
| Known as | RG-1577 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707394 ↗ |
| Known as | Sembragilina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707394 ↗ |
| Action | Inhibit | “Sembragiline is a potent, selective, long-acting, and reversible MAO-B inhibitor” PMID 28550255 ↗ 2017 |
| Modality | Small molecule | — CHEMBL3707394 ↗ |
| Route | Oral | “Participants will receive RO4602522 orally once daily for 12 months.” NCT01677754 ↗ |